I-123 Brain Studies of Serotonin Metabolism in Psychiatric Patients and Normal Volunteers

Launched by NATIONAL INSTITUTE OF MENTAL HEALTH (NIMH) · Nov 3, 1999

Keywords

ClinConnect Summary

Abnormalities in the re-uptake of dopamine and serotonin have been described in various neuropsychiatric disorders and substance abuse. \[I-123\] Beta-CIT is a recently developed radioligand for SPECT imaging of dopamine and serotonin transporters. \[I-123\]Beta-CIT SPECT has been used at the SPECT-Lab of the Clinical Brain Disorders Branch in over fifty subjects without adverse events. Due to the trace concentrations used, a pharmacological effect of Beta-CIT is unlikely and has not been observed. The purpose of this study is to use Beta-CIT and SPECT to study the expression of dopamine an...

Gender

ALL

Eligibility criteria

• INCLUSION CRITERIA:
• • No Axis I or Axis II diagnoses.
• EXCLUSION CRITERIA FOR ALL SUBJECTS:
• • If the pregnancy test is positive or if the woman has reason to believe she might be pregnant, she will be excluded from this study.
• • Women who are breastfeeding will be excluded from this study to avoid unwarranted risk to their children.
• • Subjects with a prior reaction to iodine, iodine compounds, or shellfish will be excluded from this study.
• • Subjects with a history of thyroid disease or dysfunction will be excluded from this study.
• • Subjects with a history of recent substance abuse will be excluded from this study.
• • Subjects with metal objects in their bodies as specified in our MRI protocol (91-M-0124) will be excluded from this study.
• • If a structural abnormality of the brain is detected on MRI, subjects will be excluded from the study.
• EXCLUSION CRITERIA FOR NORMAL CONTROLS:
• • Subjects with an Axis I or Axis II disorder will be excluded.
• • Subjects with concomitant medical or neurological disorders which require ongoing medication, or which may affect the central nervous system will be excluded.